The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
Open accessAbstract
Five to ten percent of individuals with melanoma have another affected family member, suggesting familial predisposition. Germ-line mutations in the cyclin-dependent kinase (CDK) inhibitor p16 have been reported in a subset of melanoma pedigrees, but their prevalence is unknown in more common cases of familial melanoma that do not involve large families with multiple affected members. We screened for germ-line mutations in p16 and in two other candidate melanoma genes, p19ARF and CDK4, in 33 consecutive patients treated for melanoma; these patients had at least one affected first or second degree relative (28 independent families). Five independent, definitive p16 mutations were detected (18%, 95% confidence interval: 6%, 37%), including one nonsense, one disease-associated missense, and three small deletions. No mutations were detected in CDK4. Disease-associated mutations in p19ARF, whose transcript is derived in part from an alternative codon reading frame of p16, were only detected in patients who also had mutations inactivating p16. We conclude that germ-line p16 mutations are present in a significant fraction of individuals who have melanoma and a positive family history.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818
Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
Koh, J., Enders, G. H., David Dynlacht, B., & Harlow, E. (1995) · Nature · doi:10.1038/375506a0 · Cited by 516
Mutations associated with familial melanoma impair p16INK4 function
Ranade, K., Hussussian, C. J., Sikorski, R. S., Varmus, H. E., Goldstein, A. M., Tucker, M. A., Serrano, M., Hannon, G. J., Beach, D., & Dracopoli, N. C. (1995) · Nature Genetics · doi:10.1038/ng0595-114 · Cited by 280
Cited by
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
The p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Schadendorf, D., Fisher, D. E., Garbe, C., Gershenwald, J. E., Grob, J.-J., Halpern, A., Herlyn, M., Marchetti, M. A., McArthur, G., Ribas, A., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.3 · Cited by 613
UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer
de Gruijl, F. R., van Kranen, H. J., & Mullenders, L. H. F. (2001) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/s1011-1344(01)00199-3 · Cited by 544
The INK4A/ARF locus and its two gene products.
Sharpless, N. E., & DePinho, R. A. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80004-5 · Cited by 533
The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia
Bastian, B. C. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104658 · Cited by 513
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
p16(MTS-1/CDKN2/INK4a) in Cancer Progression
Rocco, J. W., & Sidransky, D. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5149 · Cited by 470
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo
Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., Horner, J. W., & DePinho, R. A. (1997) · Genes & Development · doi:10.1101/gad.11.21.2822 · Cited by 402
Soufir, N. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.2.209 · Cited by 386
Robertson, K. D., & Jones, P. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.11.6457 · Cited by 352
Borg, A., Sandberg, T., Nilsson, K., Johannsson, O., Klinker, M., Masback, A., Westerdahl, J., Olsson, H., & Ingvar, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1260 · Cited by 345
A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
Smalley, K. S. M. (2003) · International Journal of Cancer · doi:10.1002/ijc.10978 · Cited by 325
The INK4 family of cell cycle inhibitors in cancer
Roussel, M. F. (1999) · Oncogene · doi:10.1038/sj.onc.1202998 · Cited by 322
Integrin signaling in malignant melanoma
Kuphal, S., Bauer, R., & Bosserhoff, A.-K. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1572-1 · Cited by 289
A germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family
Randerson-Moor, J. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.1.55 · Cited by 281
Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma
Liu, L., Dilworth, D., Gao, L., Monzon, J., Summers, A., Lassam, N., & Hogg, D. (1999) · Nature Genetics · doi:10.1038/5082 · Cited by 276
Diederichs, S., Bartsch, L., Berkmann, J. C., Fröse, K., Heitmann, J., Hoppe, C., Iggena, D., Jazmati, D., Karschnia, P., Linsenmeier, M., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506055 · Cited by 253
The differential impact of p16INK4a or p19ARF deficiency on cell growth and tumorigenesis
Sharpless, N. E., Ramsey, M. R., Balasubramanian, P., Castrillon, D. H., & DePinho, R. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207074 · Cited by 224
Familial melanoma, pancreatic cancer and germline CDKN2A mutations
Goldstein, A. M. (2004) · Human Mutation · doi:10.1002/humu.9247 · Cited by 130
Sarkar-Agrawal, P., Vergilis, I., Sharpless, N. E., DePinho, R. A., & Runger, T. M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh307 · Cited by 48
Familial malignant melanoma ‐ overview
Dębniak, T. (2004) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-2-3-123 · Cited by 17
“Soufir et al showed frequent involvement of CDKN2A in French familial melanoma families (46%) whereas Fitzgerald et al identified 18% of US familial melanoma harboured CDKN2A constitutional mutations [36, 37].”
Background(1998) · doi:10.1002/(sici)1098-1004(1998)11:6
Metadata
- Authors
- FitzGerald, M. G., Harkin, D. P., Silva-Arrieta, S., MacDonald, D. J., Lucchina, L. C., Unsal, H., O'Neill, E., Koh, J., Finkelstein, D. M., Isselbacher, K. J., Sober, A. J., & Haber, D. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1996-08-06
- Volume
- 93
- Issue
- 16
- Pages
- 8541-8545
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2032918048
- Cited by
- 200
- References
- 7
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.